GlassScriptPhysician profile
Garry Mcculloch
NPI 1699065805
$4,600.42
in general payments reported to CMS, 2019-2025
27 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $422 · 2021: $663 · 2022: $704 · 2023: $911 · 2024: $547 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,908.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $747.42 | 2019-2025 | |
| Pfizer INC. | $737.88 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $535.07 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $454.33 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $402.88 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $366.25 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $331.65 | 2021-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $121.23 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Amgen INC. | $116.35 | 2019-2024 | Repatha |
| Inspire Medical Systems, INC. | $101.12 | 2024 | Inspire |
| Edwards Lifesciences Corporation | $99.91 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Pascal |
| Cvrx, INC. | $96.50 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.91 | 2022-2025 | |
| Boston Scientific Corporation | $50.75 | 2019-2024 | Watchman Flx |
| Kiniksa Pharmaceuticals, LTD. | $48.45 | 2023 | Arcalyst |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $47.09 | 2025 | Tryngolza |
| Sanofi-Aventis U.S. LLC | $41.67 | 2019 | |
| Philips North America LLC | $39.70 | 2025 | Extended Holter |
| Abbott Laboratories | $39.67 | 2022-2023 | Mitraclip |
| Merck Sharp & Dohme LLC | $24.10 | 2023 | Verquvo |
| Amarin Pharma, INC. | $23.15 | 2019 | |
| Daiichi Sankyo INC. | $20.93 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $19.52 | 2023 | Inpefa |
| Lantheus Medical Imaging, INC. | $19.30 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $17.74 | 2023 | Livalo |
| Esperion Therapeutics, INC. | $15.55 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $15.30 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garry Mcculloch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.